Compare Citius Pharmaceuticals Inc (CTXR) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Xylem, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Xylem, Inc. trades at $120.84 (market cap $28.89B). The key difference: Xylem, Inc. is far larger — about 1973.4× Citius Pharmaceuticals Inc's market cap, and Xylem, Inc. pays a 1.42% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | XYL | |
|---|---|---|
Market Cap | $14.64M | $28.89B |
Sector | Health | Industrials |
52-Week High | $1.82 | $152.95 |
52-Week Low | $0.53 | $106.34 |
Enterprise Value | $10.86M | $30.14B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
XYL trades at $121.21, showing minimal daily change. The stock maintains a bullish technical outlook with consistent earnings beats in recent quarters. Revenue grew to $9.04B in 2025 with a net margin of 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. Analyst consensus is mixed with a $153.14 price target suggesting 26% upside from current levels.
XYL offers solid fundamentals with expanding profitability and strong cash flow generation. Key risks include execution of growth initiatives and macroeconomic sensitivity. The stock presents a compelling opportunity for long-term investors seeking exposure to essential water infrastructure, though near-term volatility may persist around earnings announcements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
